

MAP Pharmaceuticals, Inc.  
Form 8-K  
February 23, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 23, 2009

**MAP PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-33719**  
(Commission  
File Number)

**20-0507047**  
(IRS Employer  
Identification No.)

**2400 Bayshore Parkway, Suite 200, Mountain View, CA**  
(Address of Principal Executive Offices)

**94043**  
(Zip Code)

Registrant's telephone number, including area code: (650) 386-3100

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

## Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

In a press release issued on February 23, 2009, MAP Pharmaceuticals, Inc. (the Company) announced results of its initial Phase 3 clinical trial of Unit Dose Budesonide ( UDB ) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 7.01. Regulation FD Disclosure.**

In a press release issued on February 23, 2009 and attached hereto as Exhibit 99.1, the Company announced results of its initial Phase 3 clinical trial of Unit Dose Budesonide ( UDB ) for the potential treatment of children with asthma.

The Company will host a conference call at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time on Monday, February 23, 2009, to update stockholders on the results of its initial Phase 3 clinical trial of Unit Dose Budesonide announced today. Callers may join the call via telephone at 888-631-5931 (domestic) or 913-312-4375 (international). Access to the live webcast will be available via the Investor Relations section of the Company's Website at [www.mappharma.com](http://www.mappharma.com). A replay will also be available within 24 hours for at least seven days following the conference call.

The information in this Item only, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of this Form 8-K. Consequently, it is not deemed filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated February 23, 2009

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 23, 2009

**MAP PHARMACEUTICALS, INC.**

By: /s/ Charlene A. Friedman  
Name: Charlene A. Friedman  
Title: Vice President, General Counsel and Secretary

**INDEX TO EXHIBITS FILED WITH**

**THE CURRENT REPORT ON FORM 8-K DATED FEBRUARY 23, 2009**

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated February 23, 2009